Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option ...

The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan”) as an inducement material to this ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

Stocks extend last week’s losses on Monday as concerns over the U.S. economy continue to weigh on the market. President ...

Under the terms of the investment, reAlpha will issue shares of its preferred stock to Mercurius in exchange for media ...

UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago. These figures are adjusted ...

Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class ...

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic ...